In support of its anti-tumor role, lower RIPK3 expression correlates with worsened patient survival in lung cancer (12), chronic lymphocytic leukemia (13), colon cancer (14), malignant mesothelioma (15), and breast cancer (16). The gene discussed is RIPK3; the disease is neoplasm.